These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 24857093)

  • 1. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
    Nilsson S
    Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
    Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
    Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
    Nilsson S
    Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
    Wilson JM; Parker C
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):911-8. PubMed ID: 27501059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
    Shirley M; McCormack PL
    Drugs; 2014 Apr; 74(5):579-86. PubMed ID: 24610703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.
    Delacruz A; Arauz G; Curley T; Lindo A; Jensen T
    Clin J Oncol Nurs; 2015 Apr; 19(2):E31-5. PubMed ID: 25840395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing, administration, and safety of radium-223: How I do it.
    Dan TD; Doyle L; Raval AJ; Pridjian A; Gomella LG; Den RB
    Can J Urol; 2016 Jun; 23(3):8301-5. PubMed ID: 27347625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
    Shore ND
    Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.
    Vogelzang NJ
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):809-819. PubMed ID: 28649893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
    Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland Ø; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D
    Eur Urol; 2016 Nov; 70(5):875-883. PubMed ID: 27344296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.
    Vogelzang NJ; Coleman RE; Michalski JM; Nilsson S; O'Sullivan JM; Parker C; Widmark A; Thuresson M; Xu L; Germino J; Sartor O
    Clin Genitourin Cancer; 2017 Feb; 15(1):42-52.e8. PubMed ID: 27613490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
    Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.
    Jacene H; Gomella L; Yu EY; Rohren EM
    Clin Genitourin Cancer; 2018 Aug; 16(4):e919-e926. PubMed ID: 29678471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
    McGann S; Horton ER
    Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical guide to the use of radium 223 dichloride.
    Den RB; Doyle LA; Knudsen KE
    Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
    Nilsson S; Cislo P; Sartor O; Vogelzang NJ; Coleman RE; O'Sullivan JM; Reuning-Scherer J; Shan M; Zhan L; Parker C
    Ann Oncol; 2016 May; 27(5):868-74. PubMed ID: 26912557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
    Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
    Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.
    Parker CC; Coleman RE; Sartor O; Vogelzang NJ; Bottomley D; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Seke M; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Kliment J; Wedel S; Boehmer S; Dall'Oglio M; Franzén L; Bruland ØS; Petrenciuc O; Staudacher K; Li R; Nilsson S
    Eur Urol; 2018 Mar; 73(3):427-435. PubMed ID: 28705540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
    Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.